Relevant bibliographies by topics / Cystic fibrosis; gene therapy; lentivirus

Academic literature on the topic 'Cystic fibrosis; gene therapy; lentivirus'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cystic fibrosis; gene therapy; lentivirus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cystic fibrosis; gene therapy; lentivirus"

1

Castellani, Stefano, and Massimo Conese. "Lentiviral Vectors and Cystic Fibrosis Gene Therapy." Viruses 2, no. 2 (January 29, 2010): 395–412. http://dx.doi.org/10.3390/v2020395.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Goldman, Mitchell J., Po-Shun Lee, Joo-Sung Yang, and James M. Wilson. "Lentiviral Vectors for Gene Therapy of Cystic Fibrosis." Human Gene Therapy 8, no. 18 (December 10, 1997): 2261–68. http://dx.doi.org/10.1089/hum.1997.8.18-2261.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mitomo, Katsuyuki, Uta Griesenbach, Makoto Inoue, Lucinda Somerton, Cuixiang Meng, Eiji Akiba, Toshiaki Tabata, et al. "Toward Gene Therapy for Cystic Fibrosis Using a Lentivirus Pseudotyped With Sendai Virus Envelopes." Molecular Therapy 18, no. 6 (June 2010): 1173–82. http://dx.doi.org/10.1038/mt.2010.13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Griesenbach, Uta, and Eric WFW Alton. "Cystic Fibrosis Gene Therapy – Not Low-hanging Fruit." European Respiratory & Pulmonary Diseases 02, no. 02 (2016): 48. http://dx.doi.org/10.17925/erpd.2016.02.02.48.

Full text
Abstract:
The last 25 years have shown that it has been comparatively slow and difficult to develop cystic fibrosis (CF) gene therapy; the lung is a complex target organ. However, research has steadily progressed and recently it was shown that non-viral gene therapy can stabilise CF lung disease. These data, in addition to the development of potent lentiviral vectors, have renewed interest in CF gene therapy within academia and industry.
APA, Harvard, Vancouver, ISO, and other styles
5

Copreni, E., M. Penzo, S. Carrabino, and M. Conese. "Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis." Gene Therapy 11, S1 (September 29, 2004): S67—S75. http://dx.doi.org/10.1038/sj.gt.3302372.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sinn, Patrick L., Melissa A. Hickey, Patrick D. Staber, Douglas E. Dylla, Scott A. Jeffers, Beverly L. Davidson, David A. Sanders, and Paul B. McCray. "Lentivirus Vectors Pseudotyped with Filoviral Envelope Glycoproteins Transduce Airway Epithelia from the Apical Surface Independently of Folate Receptor Alpha." Journal of Virology 77, no. 10 (May 15, 2003): 5902–10. http://dx.doi.org/10.1128/jvi.77.10.5902-5910.2003.

Full text
Abstract:
ABSTRACT The practical application of gene therapy as a treatment for cystic fibrosis is limited by poor gene transfer efficiency with vectors applied to the apical surface of airway epithelia. Recently, folate receptor alpha (FRα), a glycosylphosphatidylinositol-linked surface protein, was reported to be a cellular receptor for the filoviruses. We found that polarized human airway epithelia expressed abundant FRα on their apical surface. In an attempt to target these apical receptors, we pseudotyped feline immunodeficiency virus (FIV)-based vectors by using envelope glycoproteins (GPs) from the filoviruses Marburg virus and Ebola virus. Importantly, primary cultures of well-differentiated human airway epithelia were transduced when filovirus GP-pseudotyped FIV was applied to the apical surface. Furthermore, by deleting a heavily O-glycosylated extracellular domain of the Ebola GP, we improved the titer of concentrated vector severalfold. To investigate the folate receptor dependence of gene transfer with the filovirus pseudotypes, we compared gene transfer efficiency in immortalized airway epithelium cell lines and primary cultures. By utilizing phosphatidylinositol-specific phospholipase C (PI-PLC) treatment and FRα-blocking antibodies, we demonstrated FRα-dependent and -independent entry by filovirus glycoprotein-pseudotyped FIV-based vectors in airway epithelia. Of particular interest, entry independent of FRα was observed in primary cultures of human airway epithelia. Understanding viral vector binding and entry pathways is fundamental for developing cystic fibrosis gene therapy applications.
APA, Harvard, Vancouver, ISO, and other styles
7

Bradbury, Jane. "Detergent–lentiviral combination gives gene therapy hope for cystic fibrosis." Lancet 360, no. 9342 (October 2002): 1306. http://dx.doi.org/10.1016/s0140-6736(02)11359-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marquez Loza, Laura, Eric Yuen, and Paul McCray. "Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease." Genes 10, no. 3 (March 14, 2019): 218. http://dx.doi.org/10.3390/genes10030218.

Full text
Abstract:
Despite the continued development of cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs for the treatment of cystic fibrosis (CF), the need for mutation agnostic treatments remains. In a sub-group of CF individuals with mutations that may not respond to modulators, such as those with nonsense mutations, CFTR gene transfer to airway epithelia offers the potential for an effective treatment. Lentiviral vectors are well-suited for this purpose because they transduce nondividing cells, and provide long-term transgene expression. Studies in primary cultures of human CF airway epithelia and CF animal models demonstrate the long-term correction of CF phenotypes and low immunogenicity using lentiviral vectors. Further development of CF gene therapy requires the investigation of optimal CFTR expression in the airways. Lentiviral vectors with improved safety features have minimized insertional mutagenesis safety concerns raised in early clinical trials for severe combined immunodeficiency using γ-retroviral vectors. Recent clinical trials using improved lentiviral vectors support the feasibility and safety of lentiviral gene therapy for monogenetic diseases. While work remains to be done before CF gene therapy reaches the bedside, recent advances in lentiviral vector development reviewed here are encouraging and suggest it could be tested in clinical studies in the near future.
APA, Harvard, Vancouver, ISO, and other styles
9

Gui, Liqiong, Hong Qian, Kevin A. Rocco, Loreta Grecu, and Laura E. Niklason. "Efficient intratracheal delivery of airway epithelial cells in mice and pigs." American Journal of Physiology-Lung Cellular and Molecular Physiology 308, no. 2 (January 15, 2015): L221—L228. http://dx.doi.org/10.1152/ajplung.00147.2014.

Full text
Abstract:
Cellular therapy via direct intratracheal delivery has gained interest as a novel therapeutic strategy for treating various pulmonary diseases including cystic fibrosis lung disease. However, concerns such as insufficient cell engraftment in lungs and lack of large animal model data remain to be resolved. This study aimed to establish a simple method for evaluating cell retention in lungs and to develop reproducible approaches for efficient cell delivery into mouse and pig lungs. Human lung epithelial cells including normal human bronchial/tracheal epithelial (NHBE) cells and human lung epithelial cell line A549 were infected with pSicoR-green fluorescent protein (GFP) lentivirus. GFP-labeled NHBE cells were delivered via a modified intratracheal cell instillation method into the lungs of C57BL/6J mice. Two days following cell delivery, GFP ELISA-based assay revealed a substantial cell-retention efficiency (10.48 ± 2.86%, n = 7) in mouse lungs preinjured with 2% polidocanol. When GFP-labeled A549 cells were transplanted into Yorkshire pig lungs with a tracheal intubation fiberscope, a robust initial cell attachment (22.32% efficiency) was observed at 24 h. In addition, a lentiviral vector was developed to induce the overexpression and apical localization of cystic fibrosis transmembrane conductance regulator (CFTR)-GFP fusion proteins in NHBE cells as a means of ex vivo CFTR gene transfer in nonprogenitor (relatively differentiated) lung epithelial cells. These results have demonstrated the convenience and efficiency of direct delivery of exogenous epithelial cells to lungs in mouse and pig models and provided important background for future preclinical evaluation of intratracheal cell transplantation to treat lung diseases.
APA, Harvard, Vancouver, ISO, and other styles
10

McCarron, Alexandra, Chantelle McIntyre, Martin Donnelley, Patricia Cmielewski, and David Parsons. "711. Development of a Clinically-Acceptable Lentiviral Vector for Cystic Fibrosis Airway Gene Therapy." Molecular Therapy 24 (May 2016): S280—S281. http://dx.doi.org/10.1016/s1525-0016(16)33519-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cystic fibrosis; gene therapy; lentivirus"

1

Limberis, Maria. "A lentiviral gene transfer vector for the treatment of cystic fibrosis airway disease." Title page, synopsis and list of contents only, 2002. http://web4.library.adelaide.edu.au/theses/09PH/09phl735.pdf.

Full text
Abstract:
"16th September 2002." Accompanying CD contains 2 MPEG clips with accompanying text, and a copy in PDF format of: Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer / M. Limberis ... [et al.], published in Human gene therapy vol. 13 (2002). Bibliography: leaves xxix-li. This thesis focuses on modulating the physical barriers of the airway epithelium with mild detergents, so as to enhance gene transfer by a HIV-1 based lentivirus vector in vivo. The efficiency of the gene transfer was evaluated in the nasal airway of C57B1/6 mice using the Lac Z marker gene. This demonstration of lentivirus-mediated in vivo recovery of CFTR function in CF airway epithelium illustrated the potential of combining a pre-conditioning of the airway surface with a simple and brief HIV-1 based gene transfer vector exposure to produce therapeutic gene expression in the intact airway.
APA, Harvard, Vancouver, ISO, and other styles
2

Harding-Smith, Rebekka. "Gene transfer vector development to treat lung disease." Thesis, University of Oxford, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.711729.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Davies, Gwyneth. "Outcome measures for cystic fibrosis gene therapy clinical trials." Thesis, Imperial College London, 2013. http://hdl.handle.net/10044/1/28414.

Full text
Abstract:
Background: Cystic fibrosis (CF) is a life-shortening, chronic respiratory disease caused by mutations in the CFTR gene. Novel therapeutic agents such as gene therapy aim to correct CFTR and to demonstrate evidence of molecular, functional and (ultimately) clinical efficacy. It was hypothesised that currently used methods to detect these changes may be optimised to enhance sensitivity and allow quantification, and facilitate an understanding of geographical effects within the airway. Methods: Outcome measures were investigated within two UK CF Gene Therapy Consortium studies; a longitudinal observational study ('Run-In'), and a single dose gene therapy study ('Pilot') which investigated safety and functional efficacy. Measurement of airway function with spirometry and lung clearance index in the Run-In study allowed investigation of variability and change over time and comparison with other outcomes. Development of methodology and data analysis from measurements of potential difference (PD) in the nose and lung in the Pilot study allowed investigation of these as measures of functional efficacy. Results: In the Run-In study, the choice of external reference source was crucial for interpretation of spirometry outcomes. Airway physiology outcomes correlated with structural changes on chest CT however were limited in their ability to detect site of airway abnormality. There was some evidence that disease severity was associated with intra-subject variability and affected rate of change over time. In the Pilot study, airway PD was shown to change post gene therapy within individuals but the responses were not universal and depended on the definitions used. A novel method of nasal PD quantification did not improve an ability to quantify change. Conclusions: There is no single universal outcome measure in CF, but it is important to take account of the patient population in terms of disease severity. Whilst it would be inappropriate to relate PD outcomes with clinical outcomes in the Pilot study; this will be an important relationship to understand in the future in order to allow rational design of CF gene therapy clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
4

Rose, Andrew C. "Studies on the expression of the murine CFTR gene : implications for gene therapy." Thesis, University of Oxford, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.365354.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dragomir, Anca. "Approaches to Pharmacological Treatment and Gene Therapy of Cystic Fibrosis." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3845.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McKay, Tristan Rowntree. "Investigations toward gene therapy for hepatobiliary disease in cystic fibrosis." Thesis, Imperial College London, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.392184.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Scott, Emily Siân. "Improving the efficiency of liposome-mediated gene transfer for cystic fibrosis gene therapy." Thesis, University of Cambridge, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.624332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jaffe, Adam. "Assessment and feasibility of gene therapy for cystic fibrosis in children." Thesis, Imperial College London, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.589769.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jannetta, Evelyn Elena. "Qualitative study of cystic fibrosis (CF) patients' expectations of gene therapy." Thesis, University of Edinburgh, 2009. http://hdl.handle.net/1842/8745.

Full text
Abstract:
Introduction: Gene therapy is currently being developed for people with cystic fibrosis (CF), a life-threatening condition for which there is no cure. The UK CF Gene Therapy Consortium are preparing for a multi-dose gene therapy trial of sufficient duration that clinical benefit may be seen. Aims: The current study aimed to explore the expectations and beliefs of cystic fibrosis (CF) patients involved in the preparatory phase of the gene therapy trial (the Run-in study), from which participants will be selected for the multi-dose actual gene therapy trial. Method: Twelve participants (six with mild and six with moderate CF) were interviewed using a semi-structured interview. Interviews were recorded, transcribed verbatim and then analysed using a Constructivist Grounded Theory approach. Results: Since entering the Run-in study, half of the patients had increased their expectations of gene therapy being an effective future treatment. Most of the participants hoped to derive clinical benefit from the trial itself though half were unsure of what to expect. Whilst half of the participants expressed the hope of a future cure for CF, the remainder saw gene therapy only in terms of an improved treatment. Participants used several strategies to manage their expectations including not thinking too far ahead and trusting the research team. Discussion: The findings indicate that participants in the Run-in trial are generally eager to be involved in the gene therapy trial and have developed a strong sense of trust in the research team conducting the trials. The levels of optimism expressed for personal benefit from trial were higher than those from earlier studies. Some of the positive expectations were unlikely to be met by the gene therapy trial and participants risk disappointment. However other patients participated with apparently realistic expectations and it seems likely that some patients would have participated even without prospect for personal benefit. Possible areas of psychological support are discussed e.g. a standard clinical interview for all those not accepted for the gene therapy trial; screening for anxiety pre-, during and post-participation.
APA, Harvard, Vancouver, ISO, and other styles
10

Cooney, Ashley L. "Integrating viral vectors as a gene therapy approach for cystic fibrosis." Diss., University of Iowa, 2018. https://ir.uiowa.edu/etd/6083.

Full text
Abstract:
Cystic fibrosis (CF) is the most common autosomal recessive genetic disease in Caucasian populations. CF affects multiple organ systems including pancreas, liver, intestines, sweat glands, and male reproductive organs, however the leading cause of morbidity and mortality in CF patients is chronic lung disease. CF is caused by a mutant cystic fibrosis transmembrane conductance regulator (CFTR) gene which leads to chloride (Cl-) and bicarbonate (HCO3-) anion dysregulation at the airway surface. Without adequate anion exchange, thick, viscous mucus accumulates at the airway surface allowing bacterial colonization to occur. Complementing CFTR in the appropriate airway cells restores the anion channel activity in CFTR-deficient cells. The ultimate goal for CF gene therapy is to design an integrating vector that would lead to persistent and efficient expression of CFTR in the airways. Performing gene therapy experiments is dependent upon a relevant animal model. The CF pig is a large animal model similar in size, anatomy, and physiology to humans. Importantly, the CF pig recapitulates human lung disease. From the CF pig, we have learned much about CF lung disease and have developed relevant assays to measure anion channel correction. We have learned that loss of CFTR leads to a decreased airway surface ASL pH, bacterial killing ability, and increased mucus viscosity. Standardized assays have been developed to evaluate the change in current by Ussing chambers, ASL pH, bacterial killing in vivo and ASL pH and viscosity on primary airway cultures in vitro. Ultimately, these metrics allow us to make conclusions about the efficiency of CFTR restoration. Viral vectors are promising candidates for CF gene therapy. Viral vectors such as adenovirus (Ad), adeno-associated virus (AAV), and pseudotyped lentiviral vectors such as feline immunodeficiency virus (FIV) or human immunodeficiency virus (HIV) can efficiently transduce airway cells and express CFTR. Ad and AAV have both been tested in CF clinical trials, but CFTR expression was transient, if detected at all. Understanding vector biology and overcoming barriers in the lung have allowed us to improve vector delivery to the airways. However, the next major hurdle was achieving persistent expression. Ad and AAV are both transiently expressing vectors, and vector readministration is implausible due to the presence of neutralizing antibodies that develop against the vector. Creating a hybrid nonviral/viral vector in which the integrating nonviral piggyBac transposon system is delivered by an Ad or AAV vector has allowed us to achieve persistent expression in mice. In a third integrating vector system, lentiviral vectors have historically been challenging to work with due to low titer levels. However, improvement in vector purification methods have allowed us to validate a lentiviral vector as a viable gene therapy option. In total, we have validated three integrating vector systems by restoring CFTR to CF pigs to correct the phenotypic defect.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cystic fibrosis; gene therapy; lentivirus"

1

Love, Cynthia B. Genetic testing for cystic fibrosis: January 1989 through February 1997 : 1224 citations. Bethesda, Md. (8600 Rockville Pike, Bethesda 20894): U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

United States. Congress. Senate. Committee on Small Business. Research on childhood diseases by entrepreneurs: Hearing before the Committee on Small Business, United States Senate, One Hundred Third Congress, second session ... Thursday, May 26, 1994. Washington: U.S. G.P.O., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

United States. Congress. Senate. Committee on Small Business. Research on childhood diseases by entrepreneurs: Hearing before the Committee on Small Business, United States Senate, One Hundred Third Congress, second session ... Thursday, May 26, 1994. Washington: U.S. G.P.O., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Thursfield, Rebecca, Chris Orchard, Rosanna Featherstone, and Jane C. Davies. Future treatments. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0013.

Full text
Abstract:
There are only a relatively limited armoury of drugs, the majority of which are aimed at downstream symptoms of cystic fibrosis. Therapies targeting the basic defect in CF as well as continued availability of more conventional drugs are required. Progress in gene therapy has been limited by the significant barriers to gene transfer of the CF lung, but the UK is hosting a large repeated dose trial of nebulized non-viral gene therapy designed around clinically meaningful outcomes. The UK CF Gene Therapy Consortium is also seeking to develop a promising modified lentiviral approach, although this is some years off. Perhaps the exciting development of recent decades has come from small molecule CFTR modulators, driven by an understanding of basic pathophysiological mechanisms. Ivacaftor is the first drug to be licensed, having proved itself highly clinically efficacious in patients with the class-3 gating mutation G551D. The trial pipeline seeks to expand indications for this and to explore the potential of Phe508del correctors. Finally, a number of anti-inflammatory and anti-infective strategies are being pursued. The emerging global problem of antibiotic resistance is leading to exciting alternatives such as biofilm disruption and bacteriophage to be explored.
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, Benjamin Haeyul. Gene delivery to human sweat glands: A model for cystic fibrosis gene therapy. 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ryan, Jeanne. Charisma. Simon & Schuster, Limited, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Charisma. 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cystic fibrosis; gene therapy; lentivirus"

1

Porteous, D. J., and J. A. Innes. "Gene Therapy for Cystic Fibrosis." In Gene Therapy, 137–49. Basel: Birkhäuser Basel, 1999. http://dx.doi.org/10.1007/978-3-0348-7011-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Boyd, A. Christopher. "Gene and Stem Cell Therapy." In Cystic Fibrosis in the 21st Century, 221–29. Basel: KARGER, 2005. http://dx.doi.org/10.1159/000088601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sumner-Jones, Stephanie G., Deborah R. Gill, and Stephen C. Hyde. "Gene therapy for cystic fibrosis lung disease." In Gene Therapy for Autoimmune and Inflammatory Diseases, 47–64. Basel: Springer Basel, 2010. http://dx.doi.org/10.1007/978-3-0346-0165-8_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Trapnell, Bruce C. "Gene Therapy for Cystic Fibrosis Lung Disease." In The Pediatric Lung, 229–58. Basel: Birkhäuser Basel, 1997. http://dx.doi.org/10.1007/978-3-0348-8960-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Alton, Eric W. F. W. "Gene Delivery and Therapy: The Case for Cystic Fibrosis." In Targeting of Drugs 5, 15–19. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4615-6405-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Patel, Manish P., Uma G. Daryai, Mansi N. Athalye, Praful D. Bharadia, and Jayvadan Patel. "Gene Therapy and Small Molecules Used in the Treatment of Cystic Fibrosis." In Gene Delivery Systems, 139–61. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003186083-11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Carter, B. J., and T. R. Flotte. "Development of Adeno-associated Virus Vectors for Gene Therapy of Cystic Fibrosis." In Adeno-Associated Virus (AAV) Vectors in Gene Therapy, 119–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-80207-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Caplen, N. J., and E. W. F. W. Alton. "Cystic fibrosis." In Gene Therapy, 191–212. Garland Science, 2020. http://dx.doi.org/10.1201/9781003076919-11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Griesenbach, Uta, Duncan M. Geddes, and Eric W. F. W. Alton. "Cystic Fibrosis Gene Therapy." In Nonviral Vectors for Gene Therapy, 337–56. Elsevier, 1999. http://dx.doi.org/10.1016/b978-012358465-6/50027-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Davies, J. C., and E. W. F. W. Alton. "Gene therapy for cystic fibrosis: successes and challenges." In Cystic Fibrosis, 79–87. European Respiratory Society Journals Ltd, 2006. http://dx.doi.org/10.1183/1025448x.00035006.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cystic fibrosis; gene therapy; lentivirus"

1

Saleh, AD, NK Clarke, C. Meng, MR Jacobson, JC Davies, SR Durham, EWFW Alton, and U. Griesenbach. "S94 Development of assays to assess safety and efficacy of lentiviral gene therapy for cystic fibrosis." In British Thoracic Society Winter Meeting 2017, QEII Centre Broad Sanctuary Westminster London SW1P 3EE, 6 to 8 December 2017, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2017. http://dx.doi.org/10.1136/thoraxjnl-2017-210983.100.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sinadinos, AJ, A. Sergijenko, AD Saleh, NAM Nafchi, JW Hickmott, T. Gamlen, DR Gill, SC Hyde, EWFW Alton, and U. Griesenbach. "S82 Quantification of mRNA and protein from single cells for cystic fibrosis gene therapy." In British Thoracic Society Winter Meeting, Wednesday 17 to Friday 19 February 2021, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2021. http://dx.doi.org/10.1136/thorax-2020-btsabstracts.87.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sergijenko, A., A. Moiseenko, K. Pineault, NAM Nafchi, M. Chan, T. Gamlen, DR Gill, et al. "S67 Low levels of lentivirus-mediated CFTR gene transfer are sufficient to generate ion transport correction in air-liquid interface cultures from cystic fibrosis patients." In British Thoracic Society Winter Meeting, Wednesday 17 to Friday 19 February 2021, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2021. http://dx.doi.org/10.1136/thorax-2020-btsabstracts.72.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Saleh, AD, SR Durham, MH Shamji, U. Griesenbach, and EWFW Alton. "S19 Peak nasal inspiratory flow and nasal cytokines are useful biomarkers of nasal inflammation in cystic fibrosis gene therapy." In British Thoracic Society Winter Meeting 2019, QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, 4 to 6 December 2019, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2019. http://dx.doi.org/10.1136/thorax-2019-btsabstracts2019.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Collie, David, Peter Tennant, Catherine Gordon, Christina Vrettou, Alison Baker, Eilidh Baker, David Porteous, et al. "The Uk Cystic Fibrosis Gene Therapy Consortium: Normal Values And Reproducibility Of Forced Expiratory Flow Volume Curves In Sheep." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a2176.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cystic fibrosis; gene therapy; lentivirus' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography